Adaptive Biotechnologies Corporation
ADPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.18 | -0.06 | 0.17 | -0.50 |
| FCF Yield | -11.20% | -23.61% | -18.40% | -6.46% |
| EV / EBITDA | -7.18 | -3.92 | -6.32 | -20.23 |
| Quality | ||||
| ROIC | -36.00% | -38.98% | -26.48% | -25.65% |
| Gross Margin | 59.72% | 55.63% | 68.75% | 68.06% |
| Cash Conversion Ratio | 0.60 | 0.69 | 0.92 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.16% | 3.33% | 23.50% | 21.97% |
| Free Cash Flow Growth | 40.80% | 16.61% | 21.29% | -51.04% |
| Safety | ||||
| Net Debt / EBITDA | -0.32 | -0.18 | -0.10 | 0.14 |
| Interest Coverage | -14.04 | -16.45 | -47.24 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 8.54 | 5.23 | 4.01 | 2.56 |
| Cash Conversion Cycle | 91.06 | 113.90 | 119.04 | 159.30 |